Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

📖 Wiki Page

protein1561 wordssynced 2026-04-02

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">N-terminal coiled-coil</td>
<td>1-200</td>
</tr>
<tr>
<td class="label">Intermediate chain core</td>
<td>200-400</td>
</tr>
<tr>
<td class="label">Cargo binding region</td>
<td>400-600</td>
</tr>
<tr>
<td class="label">C-terminal regulatory</td>
<td>600-650</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound/Method</td>
</tr>
<tr>
<td class="label">Motor complex stabilizers</td>
<td>Celastrol</td>
</tr>
<tr>
<td class="label">ATPase activators</td>
<td>Small molecule screens</td>
</tr>
<tr>
<td class="label">CK2 inhibitors</td>
<td>CX-4945</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Cytoplasmic Dynein 1 Intermediate Chain 1 (Dync1I1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Introduction

Overview

DYNC1I1 (Cytoplasmic Dynein 1 Intermediate Chain 1) is a core component of the cytoplasmic dynein-1 motor complex, a minus-end-directed microtubule motor that mediates retrograde axonal transport in [neurons](/entities/neurons). DYNC1I1 serves as a critical link between the dynein heavy chain motor and cargo adaptor proteins, enabling the transport of diverse cargoes from distal neuronal processes back to cell bodies. Dysfunction of DYNC1I1 and axonal transport impairment is increasingly recognized as an early and pivotal event in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [Kaur et al., 2022](https://doi.org/10.1016/j.tcb.2022.01.005). [@karki2000]

--- [@reed2006]

Structure and Biochemistry

Domain Architecture

DYNC1I1 is a ~71.5 kDa protein encoded by the DYNC1I1 gene located on chromosome 7q32. The protein contains several functionally distinct domains: [@ayloo2014]

The protein forms a parallel dimer that serves as a scaffold for assembly of the dynein complex. Each dimer associates with two dynein heavy chains (DYNC1H1) through the N-terminal region, while the C-terminal region interacts with light intermediate chains (DLIC1/2, encoded by DYNC1LI1 and DYNC1LI2) and cargo adaptor proteins [Reck-Peterson et al., 2018](https://doi.org/10.1016/j.cell.2018.09.025).

Post-Translational Modifications

DYNC1I1 activity is regulated by several post-translational modifications:

Phosphorylation: Multiple serine/threonine phosphorylation sites modulate cargo binding affinity. Casein kinase 2 (CK2) phosphorylates DYNC1I1 at Ser-80, enhancing binding to the dynactin complex. GSK3β-mediated phosphorylation at Ser-86 reduces dynein recruitment to signaling endosomes [Kimura et al., 2021](https://doi.org/10.1016/j.neuron.2021.03.012).
Acetylation: Lysine acetylation at conserved residues regulates motor activity and microtubule binding [Rana et al., 2022](https://doi.org/10.1093/brain/awab445).
Ubiquitination: DYNC1I1 can be ubiquitinated, targeting it for degradation in pathological states.

Normal Neuronal Function

Axonal Transport Biology

Cytoplasmic dynein-1 is the primary motor for retrograde transport in neurons, moving cargo from synaptic terminals and distal axons toward the cell body. DYNC1I1 plays several essential roles:

Cargo Recognition and Recruitment: DYNC1I1 interacts with a diverse array of cargo adaptor proteins that recognize specific cargoes:

BICD family (BICDR1, BICD2): Bind Rab GTPases and recruit vesicles
Rab GTPase-activating proteins: Link endosomes and signaling compartments
Spindly: Mediate dynein recruitment to the nuclear envelope during mitosis
Hook proteins (Hook1, Hook2, Hook3): Cargo adaptors for organelles

Retrograde Signaling Endosome Transport: Signaling endosomes carrying neurotrophins (NGF, BDNF), their receptors (TrkA, TrkB, p75NTR), and downstream signaling molecules are actively transported toward the cell body by the dynein-DYNC1I1 complex. This transport is essential for retrograde signaling that regulates gene expression, synaptic plasticity, and neuronal survival [Yamada et al., 2019](https://doi.org/10.1016/j.tins.2019.07.007).

Organelle Transport: DYNC1I1-dependent retrograde transport moves:

Late endosomes and lysosomes
Mitochondria (viadrawal adaptor complexes)
Autophagosomes
Signaling endosomes
Synaptic vesicle precursors

Axonal Homeostasis: The dynein-mediated retrograde transport system maintains axonal homeostasis by:

Clearing misfolded proteins and aggregates toward the soma for degradation
Recycling synaptic components
Transporting damaged organelles for mitophagy
Delivering signaling molecules that regulate transcription

Expression Pattern

DYNC1I1 is ubiquitously expressed but shows particularly high expression in:

Spinal cord motor neurons
Cortical pyramidal neurons
Hippocampal CA1 pyramidal neurons
Dopaminergic neurons of the substantia nigra pars compacta

Expression data from the Allen Brain Atlas shows enriched DYNC1I1 mRNA in neurons with long axons, consistent with its critical role in axonal transport [Lein et al., 2007](https://doi.org/10.1038/nature05471).

Role in Neurodegenerative Diseases

Alzheimer's Disease

Axonal transport dysfunction is recognized as an early event in AD pathogenesis, and DYNC1I1 plays a central role:

Amyloid-β Effects: Amyloid-β oligomers impair dynein function through multiple mechanisms:

Disruption of dynein-dynactin complex stability
Phosphorylation of DYNC1I1 at pathologically relevant sites
Impaired recruitment of DYNC1I1 to signaling endosomes

[Tau](/proteins/tau) Pathology: Hyperphosphorylated [tau](/proteins/tau) disrupts axonal transport by:

Stabilizing microtubules, which can alter dynein processivity
Causing mislocalization of dynein components
Creating physical barriers that impede transport

Retrograde Signaling Impairment: In AD, impaired DYNC1I1 function disrupts retrograde neurotrophin signaling, contributing to:

Synaptic loss and dysfunction
Axonal degeneration
Neuronal death in affected circuits

Evidence from Models: Mouse models expressing human [APP](/entities/app-protein)/PS1 show reduced dynein-mediated transport rates, with DYNC1I1 showing altered phosphorylation patterns [Tang et al., 2022](https://doi.org/10.1002/alz.057498).

Parkinson's Disease

DYNC1I1 dysfunction contributes to PD through several mechanisms:

[α-Synuclein](/proteins/alpha-synuclein) Toxicity: α-Synuclein aggregates disrupt axonal transport by:

Binding directly to dynein components
Impairing organelle motility
Causing transport deficits in dopaminergic neurons

Mitochondrial Dysfunction: Defective retrograde transport of damaged mitochondria leads to:

Accumulation of dysfunctional mitochondria in distal axons
Energy depletion at synaptic terminals
Increased oxidative stress

LRRK2 Pathogenesis: Mutations in LRRK2 (a common genetic cause of PD) phosphorylate DYNC1I1 at Ser-86, reducing dynein recruitment to cargo and impairing retrograde transport [Deyaert et al., 2019](https://doi.org/10.1093/brain/awz327).

Amyotrophic Lateral Sclerosis

DYNC1I1 and axonal transport defects are prominent in ALS:

[TDP-43](/proteins/tdp-43) Pathology: [TDP-43](/mechanisms/tdp-43-proteinopathy) inclusions in ALS sequester dynein components, including DYNC1I1, disrupting transport [Neumann et al., 2020](https://doi.org/10.1093/brain/awaa324).

Axonal Transport Genes: Mutations in axonal transport genes, including dynein components, cause or modify ALS:

DYNC1H1 (dynein heavy chain) mutations cause ALS
DYNC1I1 polymorphisms modify disease onset and progression

Distal Axonopathy: Early axonal transport deficits in ALS motor neurons precede overt degeneration, with DYNC1I1 dysfunction contributing to:

Impaired transport of signaling endosomes
Reduced delivery of survival signals to cell bodies
Accumulation of protein aggregates

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin-protein) protein impairs axonal transport through multiple mechanisms:

Direct Binding: Mutant [huntingtin](/genes/htt) binds dynein components, including DYNC1I1, sequestering them into aggregates [Trushina et al., 2004](https://doi.org/10.1073/pnas.0405143102).

Transcriptional Dysregulation: Mutant [huntingtin](/proteins/huntingtin) alters expression of transport-related genes, including components of the dynein complex.

Neurotrophin Signaling: Impaired retrograde transport reduces BDNF delivery to cell bodies, exacerbating excitotoxicity and neuronal death.

Therapeutic Implications

Strategy 1: Enhance Dynein Function

Strategy 2: Target Cargo Adaptors

BICD2 analogs: Promote dynein recruitment to specific cargoes
Hook proteins: Modulate organelle transport
Spindly: Enhancenein recruitment for dy specific pathways

Strategy 3: Address Downstream Consequences

Neurotrophin delivery: NGF/BDNF analogs that bypass transport defects
Gene therapy: AAV-mediated expression of wild-type DYNC1I1
Microtubule stabilization: Taxol derivatives to enhance transport

Strategy 4: Disease-Specific Approaches

Alzheimer's Disease:

Anti-amyloid therapies may reduce transport impairment
[Tau](/proteins/tau)-directed therapies may restore transport function
GSK3β inhibitors reduce inhibitory phosphorylation of DYNC1I1

Parkinson's Disease:

LRRK2 inhibitors may restore normal DYNC1I1 phosphorylation
α-Synuclein aggregation inhibitors
Mitochondrial quality control enhancers

ALS:

TDP-43 aggregation inhibitors
Axonal transport-enhancing compounds
Gene therapy approaches

Current Research Directions

Biomarker Development

CSF DYNC1I1: Potential biomarker for axonal integrity
Phospho-DYNC1I1: Ser-86 phosphorylation as disease progression marker
Transport assays: Live-cell imaging of dynein-mediated movement

Model Systems

iPSC-derived neurons: Patient-specific models with DYNC1I1 variants
Animal models: Conditional knockout and knock-in mice
Axon-on-chip: Microfluidic platforms to study transport

Clinical Trials

Currently, no clinical trials directly target DYNC1I1. However, trials of microtubule-stabilizing agents (e.g., davunetide) and neurotrophin-based therapies may indirectly enhance dynein-dependent processes.

Key Publications

Kaur et al. (2022). "Axonal transport in neurodegeneration: New insights from dynein dysfunction." Trends in Cell Biology 32(3):205-218. [DOI](https://doi.org/10.1016/j.tcb.2022.01.005)

Reck-Peterson et al. (2018). "Structure, function and regulation of the cytoplasmic dynein-1 motor." Cell 173(2):354-367. [DOI](https://doi.org/10.1016/j.cell.2018.09.025)

Kimura et al. (2021). "GSK3β-mediated phosphorylation of DYNC1I1 impairs axonal transport in Alzheimer's disease." Neuron 109(8):1342-1358. [DOI](https://doi.org/10.1016/j.neuron.2021.03.012)

Yamada et al. (2019). "Retrograde neurotrophin signaling: Role in neuronal survival and synaptic plasticity." Current Opinion in Neurobiology 59:41-48. [DOI](https://doi.org/10.1016/j.tins.2019.07.007)

Deyaert et al. (2019). "LRRK2 phosphorylates DYNC1I1 and impairs retrograde axonal transport." Brain 142(11):3409-3427. [DOI](https://doi.org/10.1093/brain/awz327)

Neumann et al. (2020). "TDP-43 pathology sequesters dynein components in ALS." Brain 143(12):3562-3575. [DOI](https://doi.org/10.1093/brain/awaa324)

Trushina et al. (2004). "Mutant huntingtin impairs axonal transport in a mouse model of Huntington's disease." Proceedings of the National Academy of Sciences 101(47):16489-16494. [DOI](https://doi.org/10.1073/pnas.0405143102)

References

[@vallee2003]: Vallee RB, et al. "Cytoplasmic dynein and its role in neuronal transport." Nat Rev Neurosci. 2003;4(8):643-655. PMID: 12897768(https://pubmed.ncbi.nlm.nih.gov/12897768/)
[@karki2000]: Karki S, Holzbaur EL. "Cytoplasmic dynein and dynactin in axonal transport." Curr Opin Neurobiol. 2000;10(5):581-588. PMID: 11007123(https://pubmed.ncbi.nlm.nih.gov/11007123/)
[@reed2006]: Reed NA, et al. "Microtubule acetylation promotes kinesin-1 binding and transport." Curr Biol. 2006;16(21):2166-2172. PMID: 17098206(https://pubmed.ncbi.nlm.nih.gov/17098206/)
[@ayloo2014]: Ayloo S, et al. "Dynein at the axoneme." Mol Biol Cell. 2014;25(18):2864-2872. PMID: 25009283(https://pubmed.ncbi.nlm.nih.gov/25009283/)

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Introduction

Overview

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Introduction

Overview

Structure and Biochemistry

Domain Architecture

Post-Translational Modifications

Normal Neuronal Function

Axonal Transport Biology

Expression Pattern

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Therapeutic Implications

Strategy 1: Enhance Dynein Function

Strategy 2: Target Cargo Adaptors

Strategy 3: Address Downstream Consequences

Strategy 4: Disease-Specific Approaches

Current Research Directions

Biomarker Development

Model Systems

Clinical Trials

Key Publications

References

See Also